These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22153931)

  • 21. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells.
    Bergtold A; Desai DD; Gavhane A; Clynes R
    Immunity; 2005 Nov; 23(5):503-14. PubMed ID: 16286018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
    Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
    Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
    Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of apoptosis-resistant T cell-activating dendritic cells promotes T helper type-2 response and IgE antibody production.
    Arques JL; Regoli M; Bertelli E; Nicoletti C
    Mol Immunol; 2008 Apr; 45(8):2177-86. PubMed ID: 18237782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mode of action of immunological adjuvants.
    Allison AC
    Dev Biol Stand; 1998; 92():3-11. PubMed ID: 9554254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
    Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
    van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
    Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting antigens to dendritic cells in vivo.
    Tacken PJ; Torensma R; Figdor CG
    Immunobiology; 2006; 211(6-8):599-608. PubMed ID: 16920498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-regulation of CD86 by CD80 differentially regulates T helper responses from Mycobacterium tuberculosis secretory antigen-activated dendritic cell subsets.
    Balkhi MY; Latchumanan VK; Singh B; Sharma P; Natarajan K
    J Leukoc Biol; 2004 May; 75(5):874-83. PubMed ID: 14966193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity.
    Stubbs AC; Martin KS; Coeshott C; Skaates SV; Kuritzkes DR; Bellgrau D; Franzusoff A; Duke RC; Wilson CC
    Nat Med; 2001 May; 7(5):625-9. PubMed ID: 11329066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of dendritic cells in the regulation of class I restricted cytotoxic T lymphocyte responses.
    Boog CJ; Boes J; Melief CJ
    J Immunol; 1988 May; 140(10):3331-7. PubMed ID: 2452183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting lymphocyte Peyer's patch adhesion molecule-1: a relay approach to gut immunization.
    McKenzie BS; Corbett AJ; Brady JL; Boyle JS; Rockman SP; Lew AM
    Vaccine; 2005 May; 23(28):3668-78. PubMed ID: 15882527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving vaccines by targeting antigens to dendritic cells.
    Shortman K; Lahoud MH; Caminschi I
    Exp Mol Med; 2009 Feb; 41(2):61-6. PubMed ID: 19287186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of B cell responses to Clec9A-targeted antigen.
    Park HY; Light A; Lahoud MH; Caminschi I; Tarlinton DM; Shortman K
    J Immunol; 2013 Nov; 191(10):4919-25. PubMed ID: 24123689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting nanoparticles to dendritic cells for immunotherapy.
    Cruz LJ; Tacken PJ; Rueda F; Domingo JC; Albericio F; Figdor CG
    Methods Enzymol; 2012; 509():143-63. PubMed ID: 22568905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
    Li J; Ahmet F; Sullivan LC; Brooks AG; Kent SJ; De Rose R; Salazar AM; Reis e Sousa C; Shortman K; Lahoud MH; Heath WR; Caminschi I
    Eur J Immunol; 2015 Mar; 45(3):854-64. PubMed ID: 25487143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights into antigen encounter by B cells.
    Le Roux D; Niedergang F
    Immunobiology; 2012 Dec; 217(12):1285-91. PubMed ID: 22883562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cell targeted vaccines: Recent progresses and challenges.
    Chen P; Liu X; Sun Y; Zhou P; Wang Y; Zhang Y
    Hum Vaccin Immunother; 2016 Mar; 12(3):612-22. PubMed ID: 26513200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.
    Chappell CP; Giltiay NV; Dresch C; Clark EA
    Int Immunol; 2014 Jan; 26(1):3-11. PubMed ID: 24285828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.